🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the effort against superbug strains of the infection, according to scientists.

A Worldwide Health Concern

Gonorrhoea infections are on the rise globally, with figures suggesting over 82 million new cases each year. Notably increased rates are seen in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices presently on offer.”

Health officials are increasingly worried about the rise in antibiotic-resistant strains. The WHO has designated it as a "critical concern". A tracking program showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists believe that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This milestone represents a huge turning point in the treatment of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Data and Worldwide Availability

As per findings detailed in a prominent scientific publication, the new drug cured more than 90% of genital gonorrhoea infections. This puts it on an similar efficacy with the current standard treatment, which involves a dual-drug approach. The study included over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to license and sell the drug in numerous low-income and middle-income countries.

Clinicians treating patients have shared positive views. Access to a easy-to-administer therapy like this is hailed as a "critical tool" for gonorrhoea control. This is deemed crucial to lessen the impact of the illness for patients and to stop the proliferation of untreatable gonorrhoea worldwide.